The Korean guideline for cervical cancer screening.
10.5124/jkma.2015.58.5.398
- Author:
Kyung Jin MIN
1
;
Yoon Jae LEE
;
Mina SUH
;
Chong Woo YOO
;
Myong Cheol LIM
;
Jaekyung CHOI
;
Moran KI
;
Yong Man KIM
;
Jae Weon KIM
;
Jea Hoon KIM
;
Eal Whan PARK
;
Hoo Yeon LEE
;
Sung Chul LIM
;
Chi Heum CHO
;
Sung Ran HONG
;
Ji Yeon DANG
;
Soo Young KIM
;
Yeol KIM
;
Won Chul LEE
;
Jae Kwan LEE
Author Information
1. Department of Obstetrics and Gynecology, Korea University Medical Center, Seoul, Korea. jklee38@gmail.com
- Publication Type:Original Article
- Keywords:
Papanicolaou test;
Mass screening;
Uterine cervical neoplasms
- MeSH:
Developed Countries;
Female;
Humans;
Incidence;
Korea;
Mass Screening*;
Papanicolaou Test;
Papilloma;
Uterine Cervical Neoplasms*
- From:Journal of the Korean Medical Association
2015;58(5):398-407
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
The incidence rate of cervical cancer in Korea is still higher than in other developed countries, notwithstanding the national mass screening program. Furthermore, a new method has been introduced in cervical cancer screening. Therefore, the committee for cervical cancer screening in Korea updated the recommendation statement established in 2002. The new version of the guideline was developed by the committee using evidence-based methods. The committee reviewed the evidence for the benefits and harms of the Papanicolaou test, liquid-based cytology, and human papilloma virus (HPV) testing, and reached conclusions after deliberation. The committee recommends screening for cervical cancer with cytology (papanicolaou test or liquid-based cytology) every three years in women older than 20 years of age (recommendation A). The combination test (cytology with HPV test) is optionally recommended after taking into consideration individual risk or preference (recommendation C). The current evidence for primary HPV screening is insufficient to assess the benefits and harms of cervical cancer screening (recommendation I). Cervical cancer screening can be terminated at the age of 74 years if more than three consecutive negative cytology reports have been confirmed within ten years (recommendation D).
